Live Breaking News & Updates on கோரஸ் பார்மா

Stay updated with breaking news from கோரஸ் பார்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Gilead Sciences, Inc. (NASDAQ:GILD) - Recap: Gilead Sciences Q1 Earnings


52-week low: $56.56
Company Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead s exposure to cell therapy and noncell therapy in oncology.
  ....

Arresto Biosciences , Corus Pharma , Gilead Sciences , Company Description , Forty Seven , கோரஸ் பார்மா , கிலியட் அறிவியல் , நிறுவனம் விளக்கம் , நாற்பது ஏழு ,